Next-gen topical antivirals

We inhibit the crucial first step in viral infection of human cells: binding of a virus surface protein (e.g., "spike protein" on SARS-Cov2) to a target human cell receptor protein (e.g., ACE2 for SARS-Cov2), attaching virus to human cell and enabling infection.

Pūrvala’s immune system-based technology binds and blocks the viral surface protein, preventing virus/human cell attachment.

- Patent-pending technology for durable topical protection against viral infection

- Safe and biocompatible: Based on molecules found in the body’s own anti-viral defense system

- Creates a natural anti-viral barrier, preventing infection through physical sequestration and viral surface binding

- Applicable to a range of pathogens including influenza, c. difficile, and SARS-Cov2 (COVID-19)

- Applications include topical skincare products (e.g., face creams, hand sanitizer, lip balm), personal protective equipment (e.g., masks, gloves) and high-touch surfaces (e.g., food service counters, instruments)

- Protection can last up to 6 hours after application